Skip to main content

Funding Opportunities

A long story about a strange way to publish funding opportunities: Or, just another day at the office

Robin BARR, Director, DEA, Division of Extramural Activities (DEA)
Here we go again. Maybe. The U.S. House and Senate appropriations committees have written large increases into their appropriations bills for NIA—again in FY 2018—to expand research into Alzheimer’s disease and Alzheimer’s disease-related dementias (AD/ADRD).

Regenerative medicine conference points to new research opportunities

Candace KERR, Health Scientist Administrator, Division of Aging Biology (DAB)
Among the initiatives launched under the 21st Century Cures Act, which brought us the Cancer Moonshot, the BRAIN initiative, and the All of Us precision medicine program, is the Regenerative Medicine Innovation Project (RMIP). NIH, in coordination with the Food and Drug Administration (FDA), is taking the lead on this exciting new venture, which seeks to accelerate clinical research on adult stem cells.

A new era of clinical trials in Alzheimer’s disease and related dementias

Laurie RYAN, Chief, Dementias of Aging Branch, Division of Neuroscience (DN)
You may have already heard that the NIA has awarded a new cooperative agreement establishing the Alzheimer’s Clinical Trial Consortium (ACTC). We expect the ACTC to accelerate and expand studies for therapies in Alzheimer’s disease and related dementias. We hope you’ve also heard that the funding opportunity for ACTC trials is open. The first submission date for applications is March 29 and we strongly encourage interested investigators to reach out to the ACTC leadership and NIA well in advance.

Targeting a prize for Alzheimer's and related dementias research

Richard HODES, Director, Office of the Director (OD)
In December 2016, the President signed the 21st Century Cures Act (P.L. 114-255)—legislation that included many components relevant to the NIH—into law. One requires the NIH to support and report on prize competitions in biomedical research that can advance a field and potentially improve health outcomes. NIA now stands ready to join the action, by initiating the first step in a prize for Alzheimer’s disease and related dementias (ADRD) research.

The first cleared concepts for FY 2018

Marie BERNARD, Deputy Director, Office of the Director (OD)
The National Advisory Council on Aging met here on the NIH campus on September 26–27. Among several actions by the Council was the approval of eight new concepts for Funding Opportunity Announcements (FOAs). The lively discussion around these concepts is always one of the highlights of this two-day meeting, with conversations and conjecture often continuing into the corridors.

Let your research retire some of your educational debt

Robin BARR, Director, DEA, Division of Extramural Activities (DEA)
The NIH Loan Repayment Program provides up to $35,000 per year for qualified researchers to pay off student loans. The program is accepting applications now, as it does every fall, and NIA is one of several institutes involved in this important program. If the program is appropriate for you, apply now. You may be able to get part of your student loans repaid by NIA or one of the other NIH Institutes and Centers accepting applications.

FOAs: Where they come from and why you should care

Kimberly KRAMER, Health Specialist, Division of Extramural Activities (DEA)

As readers of this blog surely know, NIA publishes Funding Opportunity Announcements (FOAs) in the NIH Guide to—you guessed it—announce new opportunities to apply for funding. We use FOAs to inform potential applicants of new initiatives ranging from traditional R01 research grants to large P50 center grants and national surveys. But have you stopped to think about where an FOA originates? Read on for a behind-the-scenes look at FOA development.

The final stop on this line

Robin BARR, Director, DEA, Division of Extramural Activities (DEA)

Small smiles of satisfaction spread around the staff in my office last week. The NIH Guide published the last of our long-running saga of funding opportunity announcements (FOAs) on Alzheimer’s disease and Alzheimer’s-related dementias (ADRD). These were the concepts that the National Advisory Council on Aging approved last September (Thank you again, everyone!).

New possibilities for research training, small business research

Robin BARR, Director, DEA, Division of Extramural Activities (DEA)

The mighty push for research on Alzheimer’s disease and related dementias continues at NIA. While an earlier blog highlighted the research initiatives we have published, this chapter covers the more recent publication of two training initiatives and four small business-related initiatives.